IRIS
LO CAPUTO, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.661
NA - Nord America 1.080
AS - Asia 371
SA - Sud America 5
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.120
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.075
IE - Irlanda 1.003
SE - Svezia 279
CN - Cina 161
SG - Singapore 140
UA - Ucraina 118
IT - Italia 104
DE - Germania 41
GB - Regno Unito 39
VN - Vietnam 34
FI - Finlandia 32
FR - Francia 16
TR - Turchia 15
CZ - Repubblica Ceca 14
IR - Iran 7
BE - Belgio 3
CA - Canada 3
IN - India 3
AU - Australia 2
CL - Cile 2
CO - Colombia 2
HK - Hong Kong 2
MX - Messico 2
NL - Olanda 2
RU - Federazione Russa 2
SA - Arabia Saudita 2
AZ - Azerbaigian 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
ID - Indonesia 1
JO - Giordania 1
JP - Giappone 1
KR - Corea 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
PL - Polonia 1
RO - Romania 1
TW - Taiwan 1
Totale 3.120
Salva come PNG Salva come JPEG
Città #
Dublin 1.003
Nyköping 208
Chandler 165
Princeton 116
Singapore 89
Ashburn 87
Wilmington 73
Los Angeles 65
New York 37
Dong Ket 34
Des Moines 33
Helsinki 28
Munich 26
Dearborn 24
Jacksonville 22
London 18
Nanjing 17
Beijing 15
Gioia Del Colle 14
Shanghai 14
Washington 13
Bari 12
Brno 10
St Louis 10
Norwalk 9
Guangzhou 8
Wuhan 8
Foggia 7
Ann Arbor 6
San Mateo 6
Boardman 5
Borås 5
Ankara 4
Chicago 4
Jinhua 4
Nanchang 4
Olomouc 4
Stevenage 4
Brescia 3
Brussels 3
Hebei 3
Meda 3
Palermo 3
Seattle 3
Shenyang 3
Amsterdam 2
Barletta 2
Central 2
Cosenza 2
Coventry 2
Gunzenhausen 2
Heze 2
Jiaxing 2
Milan 2
Ningbo 2
Quanzhou 2
Redwood City 2
Riyadh 2
Rockville 2
Rome 2
Taizhou 2
Tehran 2
Valmadrera 2
Adelaide 1
Alagoinhas 1
Baku 1
Basel 1
Blackburn 1
Bologna 1
Bucharest 1
Bulgorello 1
Cerignola 1
Chieri 1
Ciampino 1
Clearwater 1
Dalian 1
Dallas 1
Dongyang 1
Frankfurt am Main 1
Garbagnate Milanese 1
Hilden 1
Huizhou 1
Istanbul 1
Jakarta 1
Komotini 1
Kunming 1
Lencloitre 1
Luxembourg 1
Medellín 1
Melbourne 1
Mexico City 1
Modena 1
Modugno 1
Mount Royal 1
Mumbai 1
Nantong 1
Naples 1
Newark 1
Nuremberg 1
Orland Park 1
Totale 2.305
Salva come PNG Salva come JPEG
Nome #
Tocilizumab and corticosteroids for covid-19 treatment in elderly patients. Journal of Gerontology and Geriatrics 71
Long-term failure of antiviral activity of Zidovudine therapy in anti-HIV positive subjects 70
Monitoraggio virologico in soggetti con infezione da HIV in trattamento con Zidovudina (AZT) 70
Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy. 69
Prevalence of hepatitis virus infections in Albanian refugees. 65
2Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A PossibleRole in the Resistance to HIV of HIV-1 Exposed Seronegative Individuals 65
Efficacy and Safety of Remdesivir over Two Waves of the Sars-CoV-2 Pandemic 63
Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2? 55
Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: A multicentre retrospective cohort study 52
Two nasal swabs may not be enough to exclude SARS-CoV-2 infection in symptomatic patients 45
Baricitinib: A chance to treat COVID-19? 43
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 41
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): Data from a real-life setting 40
Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users 40
Interleukin 21 (IL-21)/microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection 40
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 39
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience 38
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 37
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 37
Safety and heart rate changes in Covid-19 patients treated with Remdesivir 37
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection 36
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort 36
Sex and gender differences in COVID-19: an Italian local register- based study 36
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort 35
Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy 35
Lost to follow-up: a challenge over 10 years 34
A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection 33
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 33
Evaluation of the effect of protective genetic variants on cart success in hiv-1-infected patients 32
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts 31
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy 31
Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection 30
HIV rapid test in a community setting as a strategy to improve access to HIV testing: Data from a multicentre experience in Italy 30
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients 29
A role for mucosal immunity in resistance to HIV infection 28
Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPheRex Study 28
A comprehensive development agenda on tenofovir alafenamide in clinical practice 28
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia. 27
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 27
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 27
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 27
Severity of covid‐19 patients predicted by serum sphingolipids signature 27
Twenty Years Later: the Recent Trends of HIV-infection – Evidence from an Italian Region 26
. Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 26
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 26
Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission 26
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients 25
A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study 25
. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 25
Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy 25
A positively selected APOBEC3H haplotype is associated with natural resistance to HIV-1 infection 25
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 25
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 25
Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals 24
Human Immunodeficiency Virus (HIV)–Specific IgA and HIV Neutralizing Activity in the Serum of Exposed Seronegative Partners of HIV‐Seropositive Persons 24
An evolutionary analysis of antigen processing and presentation across different timescales reveals pervasive selection. 24
Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients 24
Comparison between Rules-Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients 23
Influence of Gender, Age, and Transmission Category on the Progression From HIV Seroconversion to AIDS 23
The elderly and direct antiviral agents: Constraint or challenge? 22
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 22
Seroimmunity to poliomyelitis in an Albanian immigrant population 22
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals 22
Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection 21
Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women: Data From the ICONA Foundation Study Group, Years 1997–2013 21
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology 21
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing 21
Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection 21
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation 21
Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen: Results From the EPOKA-MASTER Cohort 21
Specific Enfuvirtide Associated Mutational Pathways in HIV-1 Gp41 Are Significantly Correlated With an Increase in CD4+ Cell Count, Despite Virological Failure 21
RADAR Study Group of MASTER Cohort “Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients 21
Prevalence of hepatitis virus infections in Albanian refugees 21
Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis 20
Health response to a large and rapid influx of Albanian refugees in southern Italy, 1991 20
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors 20
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study) 20
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 20
Mucosal and Systemic Immune Activation Is Present in Human Immunodeficiency Virus–Exposed Seronegative Women 20
Enhancing care for people living with HIV: current and future monitoring approaches 20
Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men” AIDS 19
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 19
Toll-like receptor activation pathways in HIV-1 exposed seronegative individuals 19
PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection 19
The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection 19
Resistance to Dideoxynucleoside Reverse Transcriptase Inhibitors: Genotypic-Phenotypic Correlations 19
Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy 19
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome 19
Risk of Developing Specific AIDS”Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis 19
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years 19
First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006) 19
Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic 18
Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study 18
Endoplasmic reticulum aminopeptidase 2 haplotypes ply a role in modulating susceptibility to HIV infection 18
The 'immunologic advantage' of HIV-exposed seronegative individuals 18
Lipid Abnormalities in HIV-Infected Patients Are Not Correlated With Lopinavir Plasma Concentrations 18
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort 18
Human [alpha] Defensin in HIV-Exposed But Uninfected Individuals 18
Management of Chronic Hepatitis B in HIV-Coinfected Patients 17
PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection 17
Totale 2.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.413
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.413
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202052 0 0 0 3 8 16 12 1 4 1 5 2
2020/2021474 6 2 5 0 6 2 6 2 266 91 11 77
2021/2022492 81 3 3 15 30 26 12 50 63 36 24 149
2022/20231.809 164 27 90 36 35 117 12 62 1.116 94 28 28
2023/2024564 69 34 28 16 31 98 65 13 108 21 9 72
2024/2025336 196 64 70 6 0 0 0 0 0 0 0 0
Totale 3.798